Vimovo MAH Announcement

Grünenthal Pharma Limited are pleased to announce the completion of the transfer of the marketing authorisation for Vimovo (naproxen 500mg / esomeprazole 20mg) to Grünenthal Pharma Limited on March 1^st 2021.

The transfer is part of a US$ 922m deal between AstraZeneca and Grünenthal whereby Grünenthal acquired the Global rights to Vimovo (naproxen 500mg /esomeprazole 20mg) (ex US and Japan) and the European rights to Nexium (esomeprazole magnesium trihydrate).

About Vimovo

Vimovo is available in Ireland in one formulation.

• Vimovo (naproxen 500mg / esomeprazole 20mg) modified-release tablets (60)

Vimovo (naproxen 500mg/esomeprazole20mg) modified-release tablet is a fixed-dose combination of naproxen, a non-steroidal anti-inflammatory drug (NSAID) and esomeprazole, the same gastroprotective active ingredient as in Nexium. It is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing NSAID-associated gastric ulcers and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.^[1]

For further details on Vimovo please see the Summary of Product Characteristics on www.medicines.ie

Please direct any enquiries by telephone to: + 44 870 351 8960 or via e-mail to generalenquiresIE@grunenthal.com